Form 4: Corvus Pharmaceuticals Director, Scott W. Morrison, Reports Stock Option Grant

Scott W. Morrison, a director of Corvus Pharmaceuticals, reported the acquisition of stock options in a recent SEC filing.

Summary

• Scott W. Morrison, a director at Corvus Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Morrison on June 13, 2024.
• The stock options give Morrison the right to buy 15,000 shares of Corvus Pharmaceuticals common stock at an exercise price of $2.12 per share.
• The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
• The options expire on June 13, 2034.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock option grants, which is neither particularly positive nor negative. It's a neutral event in terms of sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Future Outlook

The filing does not contain any forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (15,000 shares) would need to be compared to grants given to directors at comparable companies (e.g., other small-cap biotech firms like Gritstone Bio or Agenus) to determine if it is within the typical range.
• Vesting schedules tied to continued service are also standard practice.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates